atopic dermatitis

News

Sanofi slumps despite positive eczema drug readout

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

News

Apogee's chief executive Michael Henderson

Apogee rises as long-acting eczema drug heads for phase 3

Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.

News

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.

News

Galderma adds new indication for blockbuster hope Nemluvio

Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label.

News

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis.

News

physician holds hand of a person with chronic hand eczema

LEO closes on first approval for chronic hand eczema drug

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

Sanofi slumps despite positive eczema drug readout

Apogee rises as long-acting eczema drug heads for phase 3

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Galderma adds new indication for blockbuster hope Nemluvio

Organon makes dermatology play with $1.2bn Dermavant buyout

LEO closes on first approval for chronic hand eczema drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

atopic dermatitis

Editor's Picks